Clinical trialNCT01234558CompletedPhase 2Interventional

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

SponsorNaurex, Inc, an affiliate of Allergan plcEnrollment115Major Depressive Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Benji Kurian, MD
U Texas SW Medical Center, Dallas TX
Principal Investigator
clinicaltrials.gov ↗
David Greuner, MD
CRI-WW, Philadelphia PA
Principal Investigator
clinicaltrials.gov ↗
David Krefetz, DO
CRI-WW Lordes Hospital, Willingboro NJ
Principal Investigator
clinicaltrials.gov ↗
Matthew Macaluso, MD
Clinical Research Center, Univ Kansas, Wichita KS
Principal Investigator
clinicaltrials.gov ↗
Michael Lesem, MD
Claghorn-Lesem Research Clinic, Houston TX
Principal Investigator
clinicaltrials.gov ↗
Paul Gross, MD
Lehigh Center for Clinical Research, Allentown PA
Principal Investigator
clinicaltrials.gov ↗
Raymond Manning, MD
CNRI-LA, Pico Rivera CA
Principal Investigator
clinicaltrials.gov ↗
Ronald M Burch, MD, PhD
Naurex, Inc, an affiliate of Allergan plc
Study Director
clinicaltrials.gov ↗
Stephen Murray, MD PhD
Clinilabs, New York, NY
Principal Investigator
clinicaltrials.gov ↗
Surinder Randhawa, MD
Lynn Health Sciences Institute, Oklahoma City OK
Principal Investigator
clinicaltrials.gov ↗
Vishaal Mehra, MD
Artemis Clinical Research, San Diego CA
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mulitple
Evanston, Illinois, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GLYX-13

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2011
Primary completion: 30 Jun 2012
Completion: 31 Jul 2012
Last update posted: 12 Sept 2012
Registered enrollment: 115
Registry id: NCT01234558

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.